PRL3-zumab, a first-in-class humanized antibody for cancer therapy

Min Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, Koji Kono, Abhishek Gupta, You Bin Lin, Kousaku Mimura, Jean Paul Thiery, Boon Cher Goh, Patrick Tan, Ross Soo, Cheng William Hong, Lingzhi Wang, Suling Joyce Lin, Elya Chen, Sun Young Rha, Hyun Cheol Chung, Jie Li, Sayantani Nandi, Hiu Fung YuenShu-Dong Zhang, Yeoh Khay Guan, Jimmy So, Qi Zeng

Research output: Contribution to journalArticle

1 Downloads (Pure)

Abstract

Novel, tumor-specific drugs are urgently needed for a breakthrough in cancer therapy. Herein, we generated a first-in-class humanized antibody (PRL3-zumab) against PRL-3, an intracellular tumor-associated phosphatase upregulated in multiple human cancers, for unconventional cancer immunotherapies. We focused on gastric cancer (GC), wherein elevated PRL-3 mRNA levels significantly correlated with shortened overall survival of GC patients. PRL-3 protein was overexpressed in 85% of fresh-frozen clinical gastric tumor samples examined but not in patient-matched normal gastric tissues. Using human GC cell lines, we demonstrated that PRL3-zumab specifically blocked PRL-3+, but not PRL-3–, orthotopic gastric tumors. In this setting, PRL3-zumab had better therapeutic efficacy as a monotherapy, rather than simultaneous combination with 5-fluorouracil or 5-fluorouracil alone. PRL3-zumab could also prevent PRL-3+ tumor recurrence. Mechanistically, we found that intracellular PRL-3 antigens could be externalized to become “extracellular oncotargets” that serve as bait for PRL3-zumab binding to potentially bridge and recruit immunocytes into tumor microenvironments for killing effects on cancer cells. In summary, our results document a comprehensive cancer therapeutic approach to specific antibody-targeted therapy against the PRL-3 oncotarget as a case study for developing antibodies against other intracellular targets in drug discovery.
Original languageEnglish
JournalJCI Insight
Volume1
Issue number9
DOIs
Publication statusPublished - 16 Jun 2016

Keywords

  • Gastroenterology
  • Therapeutics
  • PRL3-zumab
  • humanized antibody
  • cancer therapy

Fingerprint Dive into the research topics of 'PRL3-zumab, a first-in-class humanized antibody for cancer therapy'. Together they form a unique fingerprint.

  • Cite this

    Thura, M., Al-Aidaroos, A. Q. O., Yong, W. P., Kono, K., Gupta, A., Lin, Y. B., Mimura, K., Thiery, J. P., Goh, B. C., Tan, P., Soo, R., Hong, C. W., Wang, L., Lin, S. J., Chen, E., Rha, S. Y., Chung, H. C., Li, J., Nandi, S., ... Zeng, Q. (2016). PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight, 1(9). https://doi.org/10.1172/jci.insight.87607